Список проголосовавших за комментарий " On The Wires<ul><li>Novocure (<strong>NVCR</strong>) announced that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer after failing platinum-based therapy.</li><li>Entest BioMedical Inc.'s (<strong>ENTB</strong>) wholly owned subsidiary, Zander Therapeutics Inc., announced today publication by the United States Patent and Trademark Office of a Utility Patent application entitled «Canine Autologous Immunotherapy using Dendritic Cell Induced Cancer Killing Immunocytes». This patent application, which has a priority date of July 2015 and is assigned to Zander Therapeutics, covers the generation of a new type of cell from dog blood which possesses ability to kill tumor cells. «Currently Zander Therapeutics is pursuing a highly targeted strategy of therapeutically modifying the immune system in cats, dogs and horses using small molecule modulators of NR2F6 activity. In this particular case, the current patent publication extends the intellectual property walls that Zander is establishing by covering specific means of generating immune system cells that can be modified by the small molecules in development,» said Harry Lander, Ph.D., President and Chief Scientific Officer of Zander Therapeutics.</li><li>CB&I (<strong>CBI</strong>) announced it has been awarded a contract by Dongguan Grand Resource Science & Technology Co. Ltd. for the license and engineering design of a grassroots propane dehydrogenation unit to be built in Dongguan City, Guangdong Province, China. The unit will use CB&I's CATOFIN catalytic dehydrogenation technology and Clariant's tailor-made CATOFIN catalyst to produce 600,000 metric tons per year of propylene. This unit has been optimized to reduce equipment piece-count and lower propane consumption, resulting in low investment and operating costs.</li><li>ICU Medical (<strong>ICUI</strong>) announced results of a new multi-hospital study that shows dramatic improvements in potentially catastrophic dosing errors and drug library compliance when its Plum infusion pumps and Hospira MedNet safety software are integrated with hospitals' electronic medical records. The study showed a 52 percent decrease in the rate of PCDE's and an average of 156 overall average percent increase in compliance with a participating hospital's drug libraries after smart pump-EMR integration, which was consistent across hospitals and sustained after integration. One hospital saw a decrease in the PCDE rate of as much as 73 percent. There was also a large and statistically significant reduction in the variability in the severity of individual PCDEs. The study was performed at three US community hospitals ranging from 50 to 350 beds.</li><li>Roche (<strong>RHHBY</strong>) announced that it has signed an exclusive partnership agreement with Medtronic plc (<strong>MDT</strong>). Under the terms of the agreement, Roche will develop a dedicated Bluetooth Low Energy enabled blood glucose monitoring meter that will communicate with Medtronic's future BLE enabled insulin pump systems. The new meter will be based on Roche's innovative Accu-Chek Guide platform and will be marketed under the name Accu-Chek Guide Link. The exclusive agreement covers all markets where future BLE enabled pumps will be commercialized.</li><li>X-Chem, Inc. announced that it has expanded its collaboration with Janssen Biotech (<strong>JNJ</strong>), to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties' existing discovery and license partnership, entered into in December 2014, and was facilitated by Johnson & Johnson Innovation. This latest agreement will apply X-Chem's DEX platform to the identification of novel modulators for challenging disease targets, following the licensing of multiple series of X-Chem-discovered small molecules by Janssen in 2016. Under the terms of the agreement, X-Chem receives an upfront payment and research funding, and is eligible to receive additional payments and royalties based on the achievement of clinical, regulatory and commercial milestones.</li></ul>"